Clinical Pharmacology Unit, Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceara, Coronel Nunes de Melo 1127, 60430-270 Fortaleza, Ceara, Brazil.
Contemp Clin Trials. 2011 Mar;32(2):153-9. doi: 10.1016/j.cct.2010.10.011. Epub 2010 Oct 23.
Laxatives are much utilized, but few clinical trials assessed the efficacy of phytotherapics in the functional constipation.
The aim of this study was to evaluate the efficacy of the tincture of jalapa in the treatment of patients with functional constipation.
Double-blind, randomized, placebo-controlled clinical trial was used in this study. Seventy-six patients were assigned to two treatment groups, jalapa or placebo. The study consisted of three phases: pre-treatment, treatment, and post-treatment, each phase lasting 7 days. The mean frequency of stools, the mean consistency of stools, and the presence of pain and effort to evacuate were assessed. We monitored adverse events before, during, and after the administration of 15 mL of tincture of jalapa or placebo.
After treatment, the mean frequency of stools of the jalapa group (0.58 ± 0.25 stools/day; P < 0.0001) was higher than in the placebo group (0.36 ± 0.20 stools/day). In the pre-treatment, stool consistency, according to the Bristol scale, ranged from types 1 to 3 for both groups. The jalapa group showed improved mean consistency of stools (P = 0.0102) after treatment, approximately ranging between types 2 and 4, while the placebo group did not show statistically significant differences (P = 0.1446). The reduction of pain (P = 0.0061) and effort (P = 0.0289) in the jalapa group were statistically significant. Both treatments were well tolerated by the patients.
The tincture of jalapa was shown to be effective in the acute treatment of functional constipation.
泻剂的应用较为广泛,但很少有临床试验评估植物疗法治疗功能性便秘的疗效。
本研究旨在评估瓜蒂酊治疗功能性便秘患者的疗效。
本研究采用双盲、随机、安慰剂对照临床试验。76 名患者被分为瓜蒂组或安慰剂组。研究分为三个阶段:治疗前、治疗期和治疗后,每个阶段持续 7 天。评估粪便的平均频率、粪便的平均稠度以及疼痛和排便费力的存在情况。我们监测了在给予 15 毫升瓜蒂酊或安慰剂前后的不良反应。
治疗后,瓜蒂组的平均排便频率(0.58 ± 0.25 次/天;P < 0.0001)高于安慰剂组(0.36 ± 0.20 次/天)。在治疗前,根据布里斯托尔量表,两组的粪便稠度范围从 1 型到 3 型。瓜蒂组治疗后粪便稠度的平均改善具有统计学意义(P = 0.0102),大致在 2 型和 4 型之间,而安慰剂组则无统计学差异(P = 0.1446)。瓜蒂组疼痛(P = 0.0061)和费力(P = 0.0289)的减少具有统计学意义。两种治疗方法均被患者良好耐受。
瓜蒂酊在功能性便秘的急性治疗中显示出疗效。